Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00457106 · ClinicalTrials.gov registry record · NA
A Single-Blind Trial of Risperidone vs. Paroxetine for Treatment of Panic Attacks
A NA study, sponsored by Beth Israel Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 90
- Enrollment target
NCT00457106: Completed NA study, sponsored by Beth Israel Medical Center.
NCT00457106 is a NA study that has completed, run by Beth Israel Medical Center. The registered enrollment target is 90 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00457106, a NA study, has completed, sponsored by Beth Israel Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
Study Summary
This study compares the efficacy of risperidone to that of paroxetine in the treatment of panic attacks in patients with Panic Disorder and with Major Depressive Disorder with Panic attacks and compares the side effect profile of risperidone vs. paroxetine in treatment of panic attacks and compares response rates of risperidone vs. paroxetine in treatment of panic attacks.
Interventions
- DRUG Risperidone
- DRUG Paroxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2002-06 |
| Est. Completion | 2003-06 |
| Phase | NA |
What the finished NCT00457106 record still lists
NCT00457106 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which Risperidone is the first listed.
NCT00457106 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00457106 about?
NCT00457106 is a clinical study titled "A Single-Blind Trial of Risperidone vs. Paroxetine for Treatment of Panic Attacks". This study compares the efficacy of risperidone to that of paroxetine in the treatment of panic attacks in patients with Panic Disorder and with Major Depressive Disorder with Panic attacks and compares the side effect profile of risperidone vs. paroxetine in treatment of panic attacks and compares ...
What is the current status of trial NCT00457106?
This trial is currently completed. It is a NA study. The enrollment target is 90 participants. The study started on 2002-06. Estimated completion is 2003-06.
What interventions are being tested in trial NCT00457106?
The interventions under investigation include: Risperidone (DRUG), Paroxetine (DRUG).
Who is sponsoring clinical trial NCT00457106?
This trial is sponsored by Beth Israel Medical Center, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00457106's enrollment target sits among peer trials
90 941st of 2000 higher than 1,029 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia